



The future of API's

Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement.

Soon 2020 will start and the pharmaceutical world is moving into the future taking gigantic leaps. Be part of this near future with Fischer Chemicals AG as we constantly are following the market trends to know what our customers wants and needs.

Product	Therapeutic Category	Polymorphic form	Patent USA
Cabazitaxel	Oncology	Amorphous (Prior art)	Sep. 26, 2021
Canagliflozin	Anti-diabetic	Amorphous	Jan. 14, 2028
Carfilzomib	Oncology	Amorphous (Prior art)	Jul. 20, 2026
Dabigatran	Anti-coagulant	Form I	Dec. 28, 2021
Dapagliflozin	Anti-diabetic	Amorphous	Oct. 1, 2025
Dolutegravir	Anti-retroviral	Form I	Oct. 5, 2027
Empagliflozin	Anti-diabetic	Crystalline	Aug. 1, 2028
Enzalutamide	Oncology	Crystalline Form A (Prior art)	Dec. 6, 2025
Macitentan	Anti-hypertensive	Crystalline	Dec. 6, 2025
Pazopanib	Oncology	Prior Art	Dec. 19, 2021
Rilpivirine	Anti-retroviral	Form A	Apr. 17, 2023
Sacubitril sodium Valsartan complex	Cardiovascular	Amorphous complex	Jun.15, 2027
Sitagliptin	Anti-diabetic	Mono hydrate	Nov.24, 2026
Vildagliptin	Anti-hyperglycemic	Crystalline	Dec. 10, 2023

Origin: India, US-DMF registered

*ODMF available

Ask us for offers, samples or technical details, we're keen to support you!
Please find below our contact details.

For further information, please contact:

Mr. Rolf Tschannen
Sales Executive Latam
E-Mail: Rolf.Tschannen@fischer-group.ch

Fischer Chemicals AG,
Riesbachstrasse 57
CH-8034 Zurich / Switzerland
Phone +41 44 389 69 69
Fax +41 44 389 69 70
www.fischer-group.ch